Journal profile · Dermatology
Dermatologic Therapy
ISSN 1396-0296 · eISSN 1529-8019 · Wiley-Blackwell Publishing Ltd · UNITED STATES · Bimonthly · Founded 1996
Dermatologic Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 0.89; fully open access; APC about USD 3,110; median 199 days to acceptance (126 articles, last 24 months); community-reported acceptance: fairly easy; 122 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Dermatologic Therapy is published by Wiley-Blackwell Publishing Ltd and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases and Dermatologic Treatments and Research, together about 27.6% of its articles. Its main subfields are Dermatology. (generated from OpenAlex topic counts and CAS ranking data)
Dermatologic Therapy was founded a quarter century ago to enhance an important area in the dermatologic literature with an authoritative, scholarly source of the latest information on the treatment of diseases that affect the skin, hair, nails or accessible mucous membranes. The journal maintains an international focus of interest to a wide readership. Dermatologic Therapy invites submissions of applicable original research articles and reviews. The priorities for publication highlight scientific merit, originality, and salience to academia and the medical community. With dermatological treatments evolving rapidly, disseminating notable information and advancing knowledge in relevant areas is crucial to Dermatologic Therapy’s mission. The purview of Dermatologic Therapy includes prospective, retrospective, case-controlled, longitudinal and randomized controlled trials as well as various treatment modalities, novel techniques and instruments, and safety and efficacy studies.
From the journal's Aims & Scope
Research area (LetPub): Dermatology
Editor-in-chief Hannah WesleyPublisher website
Editorial board by country: 1 in mainland China (about 14%); most named India 2, Mainland China 1, Taiwan, China 1, Greece 1, South Africa 1 (7 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Dermatology and Skin DiseasesMedicine10.4%
- Autoimmune Bullous Skin DiseasesMedicine9.3%
- Dermatologic Treatments and ResearchMedicine7.9%
- Psoriasis: Treatment and PathogenesisImmunology and Microbiology7.8%
- Nail Diseases and TreatmentsMedicine5.2%
- melanin and skin pigmentationBiochemistry, Genetics and Molecular Biology4.8%
- Hair Growth and DisordersMedicine4.7%
- Cutaneous lymphoproliferative disorders researchMedicine4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Dermatology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Dermatology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Dermatology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASCAB AbstractsCurrent ContentsPublisher website
Other: EBSCO
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 0.89LetPub ·
- Impact factor (publisher)
- 1Publisher website ·
- Impact factor (publisher) 2025
- 1Publisher website ·
- CiteScore 2026-06
- 6.6LetPub ·
- CiteScore (publisher)
- 6.6Publisher website ·
- CiteScore (publisher) 2025
- 6.6Publisher website ·
- SJR 2026-06
- 0.8LetPub ·
- SNIP 2026-06
- 1.07LetPub ·
- h-index
- 60LetPub ·
- h-index
- 104OpenAlex ·
- i10-index
- 2,285OpenAlex ·
- 2-year mean citedness
- 0.61OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 120LetPub ·
- Articles per year (publisher) 2025
- 121Publisher website ·
- Downloads per year (publisher) 2025
- 530,640Publisher website ·
Articles by year OpenAlex count · 5,526 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 285 | 285 | 22 |
| 2025 | 122 | 122 | 115 |
| 2024 | 67 | 67 | 152 |
| 2023 | 81 | 81 | 230 |
| 2022 | 694 | 411 | 6,415 |
| 2021 | 570 | 427 | 6,984 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
199 daysMedian, submission to acceptance · P25–P75 108 days – 303 days
- Acceptance to online
- median 28 days (126 articles)
- Submission to online
- median 242 days
- Sample
- 126 articles with submission and acceptance dates (390 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 22%Publisher website ·
- Acceptance rate (publisher) 2025
- 22%Publisher website ·
- Submission to first decision
- 87 daysPublisher website ·
- Submission to first decision 2025
- 87 daysPublisher website ·
- Submission to acceptance 2025
- 227 daysPublisher website ·
- Acceptance to publication 2025
- 23 daysPublisher website ·
- Submission to publication (journal-reported)
- about 35 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,110 / GBP 1,990 / EUR 2,570 | Yes | CC BY | |
| OpenAlex | USD 2,700 / EUR 2,340 / GBP 1,990 | — | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted3
- editorialCommentary or perspective from the editorial team.Length not stated
- research articleDermatologic Therapy publishes the following types of submissions: Research Article Review Article EditorialLength not stated
- review articleSummarizes and critically evaluates existing literature on a specific topic. Should provide new insights, identify gaps, and suggest future research directions.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Preprints, Self-archiving, Trial registration / reporting guidelines
- AI use Disclosing the use of artificial intelligence (AI)
If you or your co-authors have used Artificial Intelligence Generated Content (AIGC) tools such as ChatGPT and others based on large language models (LLMs) to develop any portion of a manuscript, their use must be described transparently and in detail in the Methods section. Find more details on Wiley’s AI guidelines for researchers and Wiley’s AI policy in full in the Best Practices Guidelines on…
Source ↗Publisher website ·- Authorship Authorship
All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. You can review the Authorship section of Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics for Wiley’s definition of authorship.
Source ↗Publisher website ·- Conflicts of interest Conflicts of Interest (COIs)
A common reason for third-party complaints of published articles is an allegation that author(s) have not fully disclosed perceived conflicts of interest (COIs). Such complaints may lead to ethics investigations by the journal and publisher. Therefore, when submitting your manuscript, you should disclose any potential conflicts of interests (also referred to as “competing interests”) that might ap…
Source ↗Publisher website ·- Data availability Data Sharing
This journal encourages and peer reviews data sharing. You can learn more about data sharing in Wiley’s Data Sharing Policies resource.
Source ↗Publisher website ·- Publication ethics COPE
This journal adheres to the ethical standards set by the Committee on Publication Ethics (COPE) to uphold integrity in scholarly research and publishing. While COPE previously organized its guidance around "core practices," these have since been replaced with a topic-based structure to better reflect the evolving needs of the research community. You can learn more about this transition and explore…
Source ↗Publisher website ·- License & copyright Copyright and licensing
This is an open access journal. Authors of accepted papers pay an Article Publication Charge (APC) and their papers are published under a Creative Commons (CC) license. For more information on this journal’s APCs and licensing policy, please visit this journal’s Open Access page. Note: Some funders require authors to use a particular type of CC license. Please check directly with your funder to de…
Source ↗Publisher website ·- Open access Open access
This is an open access journal. Submissions will be subject to an Article Publication Charge (APC) if accepted and published in the journal. Please read more about APCs and whether you may be eligible for waivers or discounts through your institution, your funder, or a country waiver at Wiley Author Services.
Source ↗Publisher website ·- Peer review Peer Review Model
We follow a single-anonymized peer review model, for applicable article types. Except where otherwise stated, manuscripts are peer reviewed by at least one anonymous reviewer and an Associate or Assistant Editor. Papers authored by Editors or Editorial Board members of the journal will be sent to Editors unaffiliated with the author or institution and monitored carefully to ensure there is no peer…
Source ↗Publisher website ·- Preprints Preprint Policy
The journal accepts articles previously published on preprint servers and does not consider this to compromise the novelty of the results. Articles based on content previously made public only on a preprint server, institutional repository, or in a thesis will be considered. The preprint should be cited. You will be asked to update any pre-publication versions with a link to the final published ar…
Source ↗Publisher website ·- Self-archiving Self-Archiving definitions and policies
This journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. You can learn more by reading Wiley’s self-archiving policy.
Source ↗Publisher website ·- Trial registration / reporting guidelines Reporting guidelines
Authors are strongly encouraged to use appropriate reporting guidelines when preparing and submitting manuscripts, to maximize transparency and reproducibility. Our editors and reviewers are also encouraged to use them in the review process. Completed checklists should be provided in the supplementary files on submission. We particularly encourage the use of: Wiley Biological and Biomedical Scienc…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell Publishing Ltd
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1996
- ISSN
- 1396-0296
- Electronic ISSN
- 1529-8019
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Dermatologic Therapy
What CAS zone is Dermatologic Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Dermatologic Therapy is in Zone 3 of Medicine, and in Zone 3 of the minor category Dermatology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Dermatologic Therapy?
The latest impact factor listed by LetPub is 0.89; CiteScore 6.6, h-index 104.
How long does peer review take at Dermatologic Therapy?
Based on the dates recorded on 126 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 199 days (interquartile range 108–303 days); authors report an average review time of about 3 months; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 22% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Dermatologic Therapy based?
Of the 7 board members whose country the journal's board page names, 1 (about 14%) are in mainland China; the countries named most often are India (2), Mainland China (1) and Taiwan, China (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Dermatologic Therapy?
According to LetPub and DOAJ records, Dermatologic Therapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Embase, CAS, CAB Abstracts and Current Contents; that list has not been checked against each database.
Is Dermatologic Therapy open access, and what is the APC?
Dermatologic Therapy is a fully open-access journal. APC about USD 3,110.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .